Terms: = Prostate cancer AND PMS2, HNPCC4, 5395, ENSG00000122512, H_DJ0042M02_9, PMSL2, PMS2CL AND Treatment
1824 results:
1. [Application of 1470 nm semiconductor laser in the treatment of benign prostatic hyperplasia in ultra-aged patients].
Wu D; Yi XM; Wei HX; Zhang KX; Shi CJ; Shi XQ; Xu ZY; Fu D
Zhonghua Nan Ke Xue; 2023 Sep; 29(9):831-836. PubMed ID: 38639597
[TBL] [Abstract] [Full Text] [Related]
2. A phase I study of docetaxel plus synthetic lycopene in metastatic prostate cancer patients.
Lilly MB; Wu C; Ke Y; Chen WP; Soloff AC; Armeson K; Yokoyama NN; Li X; Song L; Yuan Y; McLaren CE; Zi X
Clin Transl Med; 2024 Mar; 14(3):e1627. PubMed ID: 38515274
[TBL] [Abstract] [Full Text] [Related]
3. Compliance With NCCN Guidelines for Evaluation and treatment of Anemia Among Patients With Solid Tumors.
Hufnagel DH; Bos LM; Brown AJ; Prescott LS
J Natl Compr Canc Netw; 2024 Mar; 22(3):. PubMed ID: 38489926
[TBL] [Abstract] [Full Text] [Related]
4. Combination of navitoclax (Bcl-2 and Bcl-xL inhibitor) and Debio-0932 (Hsp90 inhibitor) suppresses the viability of prostate cancer cells via induction of apoptotic signaling pathway.
Asdemir A; Özgür A
Med Oncol; 2024 Mar; 41(4):83. PubMed ID: 38436810
[TBL] [Abstract] [Full Text] [Related]
5. A phase 2 study of AZD4635 in combination with durvalumab or oleclumab in patients with metastatic castration-resistant prostate cancer.
Falchook GS; Reeves J; Gandhi S; Spigel DR; Arrowsmith E; George DJ; Karlix J; Pouliot G; Hattersley MM; Gangl ET; James GD; Thompson J; Russell DL; Patel B; Kumar R; Lim E
Cancer Immunol Immunother; 2024 Mar; 73(4):72. PubMed ID: 38430405
[TBL] [Abstract] [Full Text] [Related]
6. Correlation between Selenium and Zinc Levels and Survival among prostate cancer Patients.
Pietrzak S; Marciniak W; Derkacz R; Matuszczak M; Kiljańczyk A; Baszuk P; Bryśkiewicz M; Sikorski A; Gronwald J; Słojewski M; Cybulski C; Gołąb A; Huzarski T; Dębniak T; Lener MR; Jakubowska A; Kluz T; Scott RJ; Lubiński J
Nutrients; 2024 Feb; 16(4):. PubMed ID: 38398851
[TBL] [Abstract] [Full Text] [Related]
7. Harvesting the Power of Green Synthesis: Gold Nanoparticles Tailored for prostate cancer Therapy.
Oliveira M; Sousa A; Sá S; Soares S; Pereira AC; Rocha AC; Pais P; Ferreira D; Almeida C; Luís C; Lima C; Almeida F; Gestoso Á; Duarte MC; Barata P; Martins-Mendes D; Baylina P; Pereira CF; Fernandes R
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396953
[TBL] [Abstract] [Full Text] [Related]
8. A Panel-Based Mutational Signature of Mismatch Repair Deficiency is Associated With Durable Response to Pembrolizumab in Metastatic Castration-Resistant prostate cancer.
Boiarsky D; Gulhan DC; Savignano H; Lakshminarayanan G; McClure HM; Silver R; Hirsch MS; Sholl LM; Choudhury AD; Ananda G; Park PJ; Tewari AK; Berchuck JE
Clin Genitourin Cancer; 2024 Apr; 22(2):558-568.e3. PubMed ID: 38342659
[TBL] [Abstract] [Full Text] [Related]
9. Functional Outcomes After Localized prostate cancer treatment.
Al Hussein Al Awamlh B; Wallis CJD; Penson DF; Huang LC; Zhao Z; Conwill R; Talwar R; Morgans AK; Goodman M; Hamilton AS; Wu XC; Paddock LE; Stroup A; O'Neil BB; Koyama T; Hoffman KE; Barocas DA
JAMA; 2024 Jan; 331(4):302-317. PubMed ID: 38261043
[TBL] [Abstract] [Full Text] [Related]
10. Differences and Common Ground in
Farolfi A; Armstrong WR; Djaileb L; Gafita A; Hotta M; Allen-Auerbach M; Unterrainer LM; Fendler WP; Rettig M; Eiber M; Hofman MS; Hadaschik B; Herrmann K; Czernin J; Calais J; Benz MR
J Nucl Med; 2024 Mar; 65(3):438-445. PubMed ID: 38238041
[No Abstract] [Full Text] [Related]
11. The Impact of Circulating Tumor Cell HOXB13 RNA Detection in Men with Metastatic Castration-Resistant prostate cancer (mCRPC) Treated with Abiraterone or Enzalutamide.
Halabi S; Guo S; Park JJ; Nanus DM; George DJ; Antonarakis ES; Danila DC; Szmulewitz RZ; McDonnell DP; Norris JD; Lu C; Luo J; Armstrong AJ
Clin Cancer Res; 2024 Mar; 30(6):1152-1159. PubMed ID: 38236581
[TBL] [Abstract] [Full Text] [Related]
12. treatment Patterns of Bone-targeting Agents Among Solid Tumor Patients With Bone Metastases: An Analysis of Electronic Health Record Data in the United States From 2014 to 2018.
Nicholson G; Carlson KB; Hernandez RK; Schenfeld J; Cadieux B; Henry D; De Sousa Barbosa VJ; Saad H
Am J Clin Oncol; 2024 Apr; 47(4):177-184. PubMed ID: 38200688
[TBL] [Abstract] [Full Text] [Related]
13. Radiographic Progression-Free Survival and Clinical Progression-Free Survival as Potential Surrogates for Overall Survival in Men With Metastatic Hormone-Sensitive prostate cancer.
Halabi S; Roy A; Rydzewska L; Guo S; Godolphin P; Hussain M; Tangen C; Thompson I; Xie W; Carducci MA; Smith MR; Morris MJ; Gravis G; Dearnaley DP; Verhagen P; Goto T; James N; Buyse ME; Tierney JF; Sweeney C;
J Clin Oncol; 2024 Mar; 42(9):1044-1054. PubMed ID: 38181323
[TBL] [Abstract] [Full Text] [Related]
14. Bipolar androgen therapy plus nivolumab for patients with metastatic castration-resistant prostate cancer: the COMBAT phase II trial.
Markowski MC; Taplin ME; Aggarwal R; Sena LA; Wang H; Qi H; Lalji A; Sinibaldi V; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Sanin DE; Yegnasubramanian S; Gomes-Alexandre C; Ozbek B; Jones T; De Marzo AM; Denmeade SR; Antonarakis ES
Nat Commun; 2024 Jan; 15(1):14. PubMed ID: 38167882
[TBL] [Abstract] [Full Text] [Related]
15. Investigation of iso-propylchaetominine anticancer activity on apoptosis, cell cycle and Wnt signaling pathway in different cancer models.
Karamad V; Sogutlu F; Ozkaya FC; Shademan B; Ebrahim W; El-Neketi M; Avci CB
Fitoterapia; 2024 Mar; 173():105789. PubMed ID: 38158162
[TBL] [Abstract] [Full Text] [Related]
16. Phase 2 trial of a DNA vaccine (pTVG-HP) and nivolumab in patients with castration-sensitive non-metastatic (M0) prostate cancer.
McNeel DG; Emamekhoo H; Eickhoff JC; Kyriakopoulos CE; Wargowski E; Tonelli TP; Johnson LE; Liu G
J Immunother Cancer; 2023 Dec; 11(12):. PubMed ID: 38101860
[TBL] [Abstract] [Full Text] [Related]
17. Estimation of absorbed dose to salivary glands in mCRPC patients undergoing 177 Lu- PSMA-617 radioligand therapy using quantitative SPECT-CT at single time point: a single-center feasibility study.
Kaur K; Nagi S; Satapathy S; Aggarwal P; Sood A; Mittal BR
Nucl Med Commun; 2024 Feb; 45(2):115-120. PubMed ID: 37982573
[TBL] [Abstract] [Full Text] [Related]
18. The Molecular, Immunologic, and Clinicodemographic Landscape of MYC-Amplified Advanced prostate cancer.
Jin WH; Zhang L; Graf R; Raskina K; Tukachinsky H; Huang RSP; McGregor K; Alshalalfa M; Hougen HY; Khan A; Punnen S; Schrock AB; Venstrom J; Mahal BA
Clin Genitourin Cancer; 2024 Feb; 22(1):e163-e169.e1. PubMed ID: 37978032
[TBL] [Abstract] [Full Text] [Related]
19. Racial disparities in prostate cancer mortality: a model-based decomposition of contributing factors.
Gulati R; Nyame YA; Lange JM; Shoag JE; Tsodikov A; Etzioni R
J Natl Cancer Inst Monogr; 2023 Nov; 2023(62):212-218. PubMed ID: 37947332
[TBL] [Abstract] [Full Text] [Related]
20. Preclinical Comparison of the
Koller L; Joksch M; Schwarzenböck S; Kurth J; Heuschkel M; Holzleitner N; Beck R; von Amsberg G; Wester HJ; Krause BJ; Günther T
J Nucl Med; 2023 Oct; 64(10):1654-1659. PubMed ID: 37934025
[TBL] [Abstract] [Full Text] [Related]
[Next]
